{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_4092", "batch_size": 260, "batch_pos": 187, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment uses neutral language ('plans to launch', 'could respond very quickly') to describe future plans and capabilities.", "method": "llm_batch", "batch_id": "batch_2_17944", "batch_size": 260, "batch_pos": 167, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment reports plans for a human trial and potential quick response, which are future/plan/capability and Neutral.", "method": "llm_batch", "batch_id": "batch_3_4068", "batch_size": 260, "batch_pos": 110, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_6924", "batch_size": 260, "batch_pos": 104, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports action taken and capability for future but lacks explicit calming language about the current situation.", "method": "llm_batch", "batch_id": "batch_5_11936", "batch_size": 260, "batch_pos": 101, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "'small human trial' uses a minimiser but lacks explicit scale contrast.", "method": "llm_batch", "batch_id": "batch_6_15696", "batch_size": 260, "batch_pos": 69, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment reports on plans for a human trial and potential response speed but contains no bare negation or explicit calming cue.", "method": "llm_batch", "batch_id": "batch_7_15600", "batch_size": 260, "batch_pos": 58, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"hop_idx": 8, "answer": "uncertain", "rationale": "Missing response from batch", "method": "fallback", "batch_id": "batch_8_16140", "batch_size": 260, "batch_pos": 154, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes future action ('plans to launch a small human trial') and capability ('could respond very quickly') without explicit reassurance.", "method": "llm_batch_retry", "retry": 1, "batch_id": "batch_8_16140_r1", "batch_size": 260, "batch_pos": 154, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
